STEM CELL THERAPY CLINIC BUSINESS PLAN
I. Executive Summary
Company Description
Company name: name not provided. We are a premier medical clinic launching in Scottsdale, Arizona, in 2026 that operates in the regenerative medicine and stem cell therapy sector. We provide non-surgical alternatives for chronic pain and degenerative conditions using cellular repair technology. Our clinical team is led by a board-certified Medical Director and includes specialists in orthopedics, sports medicine, and spine health. One-liner: a concierge, fee-for-service clinic delivering advanced, non-surgical regenerative care.
We offer diagnostic workups, onsite cell processing, personalized treatment plans, and outcome tracking using state-of-the-art equipment. Core activities are patient intake and assessment, image-guided biologic injections, cell processing under clinical-grade conditions, and post-procedure rehab and follow-up. What sets us apart is a high-margin, outcome-focused model paired with concierge service and advanced processing tools that meet clinical standards. Target patients are adults with chronic musculoskeletal pain and degenerative disorders seeking non-surgical options. Short-term goal: open the Scottsdale clinic and establish clinical protocols and an initial patient cohort in 2026. Long-term goal: build a regional center of excellence for regenerative therapies and replicate the clinical model across additional markets.
Problem
Millions of Americans live with chronic pain and degenerative conditions—especially people aged 40 and older with osteoarthritis and sports injuries—that limit mobility, lower quality of life, and increase reliance on pain medication. One-liner: current care leaves patients trapped in a cycle of temporary fixes.
Current standard care emphasizes symptom management—pain meds, injections, and invasive surgery with long recovery—but often does not address the underlying tissue and cellular degeneration. There is a significant gap in the U.S. market for non-surgical, long-term restorative options that target cellular causes and offer durable functional recovery.
Solution
Millions of Americans live with chronic joint pain and osteoarthritis that current care treats with temporary symptom management or risky surgery. Our clinic in Scottsdale delivers minimally invasive, autologous stem cell procedures under licensed clinical oversight to repair damaged tissue at the cellular level, reduce inflammation, and restore function with outpatient recovery and coordinated rehabilitation.
A clinic-based, minimally invasive stem cell program in Scottsdale that repairs tissue, reduces inflammation, and offers a non-surgical path back to activity.
Mission Statement
We restore health and vitality through evidence-based, non-surgical regenerative therapies, delivering personalized care focused on cellular repair and functional recovery. We commit to professional, compassionate treatment that shifts chronic pain care from management to long-term restoration. We aim to set the standard in clinical excellence and patient satisfaction for regenerative orthopedic care.
Key Success Factors
Our success rests on clinical excellence, a direct-pay model, premium patient experience, integrated rehab, and strong financial returns.
-
Specialized medical team delivering superior clinical outcomes with advanced biologic kits.
-
Direct-pay revenue model enabling financial stability and a concierge patient experience.
-
State-of-the-art facility combined with targeted marketing to high-intent, affluent consumers.
-
Integrated physical therapy ensuring comprehensive recovery and high patient retention.
-
Proven financial metrics with 32.23% IRR and a 6-month payback demonstrating scalability.
Financial Summary
Executive Summary — Financial snapshot: the clinic projects strong, positive cashflow from month one with rapid scaling to year five.
Ratio |
2026 |
2027 |
2028 |
Projected Revenue |
$3,772,000 |
$7,326,000 |
$12,862,000 |
Projected EBITDA |
$2,026,000 |
$4,572,000 |
$8,907,000 |
Expected ROI |
ROE 51.42%; IRR 32.23% |
ROE 51.42%; IRR 32.23% |
ROE 51.42%; IRR 32.23% |
Financial requirements: initial capital includes capex $695,000 and minimum cash $756,000 (total $1,451,000); breakeven Jan-26 (1 month) and expected payback in 6 months; returns consistent with ROE 51.42% and IRR 32.23%.
Outlook: the clinic reaches profitability immediately and scales to high-margin EBITDA by year five.
Funding Requirements
We require funding to cover facility buildout, medical equipment, and a 6-month operating reserve so the clinic reaches positive cash flow within one month and pays back initial investment within six months.
Categories |
Amount, USD |
Operations (first-month lease) |
$15,000 |
Facility fitout and clinical buildout |
$325,000 |
Medical equipment and IT |
$370,000 |
Laboratory equipment (refrigeration) |
$25,000 |
Product Development |
$0 |
Marketing |
$0 |
Staffing (initial hires) |
$0 |
Working capital |
$756,000 |
Total funding required |
$1,451,000 |
$1,451,000 funds launch and early operations.